Y Mishima, M Matunaka
DOI: 10.2340/0001555552211215

A new anti-tumour antibiotic called Bleomycin, isolated from Streptomyces verticillus, has been clinically evaluated for the treatment of benign DNA virus tumours and malignant cutaneous neoplasms. We found that the systemic administration of Bleomycin resulted in marked to moderate regression of prickle cell carcinoma, condyloma accuminatum and verruca vulgaris. Although systemic administration of Bleomycin for basal cell epithelioma is reported minimally effective, it is found that the lesion can be eradicated by local injection of this drug.